1 original article Fibulin-3 as a Blood and Effusion Biomarker for Pleural Harvey I. Pass, M.D., Stephen M. Levin, M.D., Michael R. Harbut, M.D., Jonathan Melamed, M.D., Luis Chiriboga, Ph.D., Jessica Donington, M.D., Margaret Huflejt, Ph.D., Michele Carbone, M.D., Ph.D., David Chia, Ph.D., Lee Goodglick, Ph.D., Gary E. Goodman, M.D., Mark D. Thornquist, Ph.D., Geoffrey Liu, M.D., Marc de Perrot, M.D., Ming-Sound Tsao, M.D., and Chandra Goparaju, Ph.D. A BS TR AC T BACKGROUND New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individualize treatment strategies. We investigated whether fibulin-3 in plasma and pleural effusions could meet sensitivity and specificity criteria for a robust biomarker. METHODS We measured fibulin-3 levels in plasma (from 92 patients with mesothelioma, 136 asbestos-exposed persons without cancer, 93 patients with effusions not due to mesothelioma, and 43 healthy controls), effusions (from 74 patients with mesothelioma, 39 with benign effusions, and 54 with malignant effusions not due to mesothelioma), or both. A blinded validation was subsequently performed. Tumor tissue was examined for fibulin-3 by immunohistochemical analysis, and levels of fibulin-3 in plasma and effusions were measured with an enzyme-linked immunosorbent assay. RESULTS Plasma fibulin-3 levels did not vary according to age, sex, duration of asbestos exposure, or degree of radiographic changes and were significantly higher in patients with pleural mesothelioma (15±7 ng per milliliter in the Detroit cohort and 113±8 ng per milliliter in the New York cohort) than in asbestos-exposed persons without mesothelioma (14±1 ng per milliliter and 24±1 ng per milliliter, respectively; P<.1). Effusion fibulin-3 levels were significantly higher in patients with pleural mesothelioma (694±37 ng per milliliter in the Detroit cohort and 636±92 ng per milliliter in the New York cohort) than in patients with effusions not due to mesothelioma (212±25 and 151±23 ng per milliliter, respectively; P<.1). Fibulin-3 preferentially stained tumor cells in 26 of 26 samples. In an overall comparison of patients with and those without mesothelioma, the receiver-operating-characteristic curve for plasma fibulin-3 levels had a sensitivity of 96.7% and a specificity of 95.5% at a cutoff value of 52.8 ng of fibulin-3 per milliliter. In a comparison of patients with earlystage mesothelioma with asbestos-exposed persons, the sensitivity was 1% and the specificity was 94.1% at a cutoff value of 46. ng of fibulin-3 per milliliter. Blinded validation revealed an area under the curve of.87 for plasma specimens from 96 asbestos-exposed persons as compared with 48 patients with mesothelioma. CONCLUSIONS Plasma fibulin-3 levels can distinguish healthy persons with exposure to asbestos from patients with mesothelioma. In conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can further differentiate mesothelioma effusions from other malignant and benign effusions. (Funded by the Early Detection Research Network, National Institutes of Health, and others.) From the Departments of Cardiothoracic Surgery (H.I.P., J.D., M.H., C.G.) and Pathology (J.M., L.C.), New York University Langone Medical Center, and the Department of Preventive Medicine, Mount Sinai School of Medicine (S.M.L.) both in New York; the National Center for Vermiculite and Asbestos-Related Cancers, Karmanos Cancer Institute, Detroit (M.R.H.); University of Hawaii Cancer Center, Honolulu (M.C.); the Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles (D.C., L.G.); Swedish Cancer Institute (G.E.G.) and Fred Hutchinson Cancer Research Center (M.D.T.) both in Seattle; and Princess Margaret Hospital, University Health Network and University of Toronto, Toronto (G.L., M.P., M.-S.T.). Address reprint requests to Dr. Pass at the Department of Cardiothoracic Surgery, NYU Langone Medical Center, 53 First Ave., 9V, New York, NY 116, or at This article was updated on October 11, 212, at NEJM.org. N Engl J Med 212;367: DOI: 1.156/NEJMoa11155 Copyright 212 Massachusetts Medical Society. n engl j med 367;15 nejm.org october 11, Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
2 Despite advances in chemotherapy, radiation therapy, and surgical management for malignant pleural mesothelioma, the median survival remains 12 months. 1 Early detection is limited by the long latency period, an inability of imaging to detect the disease at an early stage even when it is used as a screening strategy, and the lack of sensitive and specific blood-based markers. 2 Moreover, in patients with undiagnosed pleural effusion, the ability to diagnose mesothelioma is delayed by failure to include the disease in the differential diagnosis and by the lack of noninvasive mesotheliomaspecific blood-based markers. Soluble mesothelinrelated protein, the most extensively studied bloodbased mesothelioma biomarker, is limited by an overall sensitivity of 47% at 96% specificity. 3 A thrombin cleavage site impedes reproducible measurements in serum for osteopontin. 4 Using genomic techniques similar to those described for our identification of osteopontin as a mesothelioma marker 5 (see the Methods section in the Supplementary Appendix, available with the full text of this article at NEJM.org), we assessed whether plasma levels of fibulin-3 have high specificity and sensitivity for discriminating patients with mesothelioma from asbestos-exposed persons and from patients with malignant or benign pleural effusions not due to mesothelioma. Me thods Study Populations Plasma and effusion samples from patients with pleural mesothelioma, plasma samples from persons who had been exposed to asbestos but did not have mesothelioma, and plasma and effusion samples from patients with pleural effusions not due to mesothelioma (Table 1) were obtained prospectively (by the first author) at Wayne State University from 1998 through 25 (Detroit cohort) and at New York University Langone Medical Center from 25 through 211 (New York cohort). The EDTA-treated specimens were stored at 8 C. Patients with other cancers were evaluated with regard to marker specificity, including 2 with ovarian cancer, 2 with breast cancer, 2 with glioblastoma, and 31 with prostate cancer (Fig. 1A). A total of 43 healthy controls (defined as persons with benign prostatic conditions and without cancer or exposure to asbestos) were also evaluated (Fig. 1A). The study was approved by the ethics committees of all participating institutions, and all study participants provided written informed consent. The first author vouches for the accuracy and completeness of the data and analysis and the fidelity of the study to the technological and biostatistical protocols. Patients with Pleural In the Detroit cohort, 78 patients had mesothelioma. Plasma was obtained from 37 of these patients, and pleural effusions were obtained from the other 41. In the New York cohort, 64 patients had mesothelioma. Plasma was obtained from 55 of these patients; it was obtained from 18 patients 2 weeks to 18 months after cytoreductive surgery, and plasma from 6 patients was available at the time of documented disease progression. Pleural effusions were available from 33 of the 64 patients with mesothelioma, of whom 12 had matching plasma samples. The median survival among the 142 patients with mesothelioma and complete follow-up through November 211 (28 months for patients with stage I or II disease and 8 months for patients with stage III or IV disease) (Fig. S1 in the Supplementary Appendix) was consistent with that in other studies using the International Interest Group staging system. 6 Cancer-free Persons with Asbestos Exposure Of the 41 asbestos-exposed persons in the Detroit cohort with plasma samples available, 4 32 had occupational exposure to asbestos for at least 5 years (78%), 5 had occupational exposure for less than 5 years (12%), and 4 had radiographic evidence of asbestos exposure despite reporting only passive exposure (1%). In this cohort, 1 persons were foundry workers, 5 were pipe fitters, 4 were in building and construction, 4 had passive exposure in the construction business or from contact with a family member, 4 were involved in brake assembly or repair, 3 were involved in boiler repair, 2 had exposure to vermiculite insulation, 2 were plumbers, 2 were ship builders, 1 was a machinist, 1 was a tool and die worker, 1 was a millwright, 1 was a brick layer, and 1 was an electrician. Radiographic evidence of fibrosis was found in 13 persons (32%), and pleural scarring or plaques were found in 3 (73%). The New York cohort included 95 steamfitters, who provided plasma samples and underwent 1418 n engl j med 367;15 nejm.org october 11, 212 Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
3 Fibulin-3 as a Marker of Table 1. Demographic and Clinical Characteristics and Fibulin-3 Levels According to Study Cohort.* Variable Detroit Cohort New York Cohort Toronto Cohort Demographic and clinical characteristics Patients with (N = 78) Asbestos-Exposed Persons (N = 41) Patients with Effusions Not Due to (N = 53) Patients with (N = 64) Asbestos-Exposed Persons (N = 95) Patients with Effusions Not Due to (N = 4) Patients with (N = 48) Asbestos-Exposed Persons (N = 96) Age yr 65±1 64±1 63±2 65±2 59±1 62±3 64±1 65±1 Sex no. Male Female Race no. White NA NA Other NA NA Asbestos exposure no. (%) 62 (79) 41 (1) NA 45 (7) 95 (1) NA 32 (67) 96 (1) Current or former smoker no. Yes No Fibulin-3 level Plasma fibulin-3 ng/ml 15.± ±1.2 NA 112.9± ± ± ± ±2.1 Effusion fibulin-3 ng/ml Any effusion 694.4± ± ± ±22.7 Benign effusion 242.3± ±35.6 Malignant effusion 181.8± ±28.9 * Plus minus values are means ±SE. NA denotes not available. Race was self-reported. P<.1 for the comparison with patients with pleural mesothelioma in the Detroit cohort. P<.1 for the comparison between the New York cohort and the Detroit cohort. P<.1 for the comparison with patients with pleural mesothelioma in the New York cohort. P<.1 for the comparison with patients with pleural mesothelioma in the Toronto cohort. n engl j med 367;15 nejm.org october 11, Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
4 A Patients with versus All Controls 3 1 B Asbestos Exposure versus Stage I or II Plasma Fibulin-3 (ng/ml) Sensitivity, 96.7% Specificity, 95.5% 2 Cutoff, >52.82 ng/ml 95% CI for the AUC, Minus Percent Specificity 6 4 Sensitivity, 1% Specificity, 94.1% 2 Cutoff, >46.3 ng/ml 95% CI for the AUC, Minus Percent Specificity Asbestos Exposure Healthy Controls Benign Effusions Lung-Cancer Effusions Breast-Cancer Effusions Other Cancer Effusions Breast Cancer, No Effusions Ovarian Cancer Prostate Cancer Glioblastoma Plasma Fibulin-3 (ng/ml) Asbestos Exposure Stage I or II Sensitivity, 1% Specificity, 94.1% Cutoff, >46.3 ng/ml C and Cytoreductive Surgery, New York Cohort D Blinded Fibulin-3 Validation Trial 1 Plasma Fibulin-3 (ng/ml) Preoperative or Intraoperative P<.1 Postoperative P=.6 Recurrence Patient 27 Patient 269 Patient 274 Patient 587 Patient 589 Patient 966 Patient 966 Patient 1363 Patient 1373 Patient 136 Patient 161 Patient 1245 Patient 125 Patient 295 Patient 851 Patient 1189 Patient 131 Patient 1336 Plasma Fibulin-3 (ng/ml) Sensitivity, 72.9% 2 Specificity, 88.5% Cutoff, >28.96 ng/ml 95% CI for the AUC, Minus Percent Specificity Asbestos Exposure Sensitivity, 72.9% Specificity, 88.5% Cutoff, >28.96 ng/ml computed tomographic scanning between September 21 and March 211 at Mount Sinai Medical Center in New York. 7 Four of the steamfitters (4%) did not report an occupational exposure to asbestos nor did they have pleural plaques or parenchymal fibrosis. The other 91 had exposure of more than 5 years (range, 6 to 58). Sixty steamfitters (63%) had pleural scarring, 23 (24%) had plaques, and 4 (4%) had parenchymal changes. Validation Cohorts The Carotene and Retinol Efficacy Trial (CARET) 8 contributed deidentified, blinded serum samples (no plasma samples were available) to the Univer- 142 n engl j med 367;15 nejm.org october 11, 212 Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
5 Fibulin-3 as a Marker of Figure 1 (facing page). Plasma Fibulin-3 Levels. Panel A shows plasma fibulin-3 levels in patients with malignant pleural mesothelioma as compared with all other cohorts. Patients for whom matched effusions were available had higher plasma levels than patients for whom effusions were not available. The inset shows the receiver-operating-characteristic (ROC) curve for all patients with mesothelioma versus 29 controls. Panel B shows the ROC curve for patients with stage I or II mesothelioma as compared with all asbestos-exposed persons; the diagram at the bottom shows the cutoff point at highest accuracy. Panel C shows plasma fibulin-3 levels among patients with mesothelioma who underwent cytoreductive surgery and subsequently had disease progression. The fibulin-3 levels fell significantly after surgery and were higher than postoperative levels when progression occurred. Panel D shows the results of blinded fibulin-3 analysis by Princess Margaret Hospital, with an area under the ROC curve (AUC) of.87 (top) and the cutoff point at highest accuracy (bottom). CI denotes confidence interval. sity of California, Los Angeles, and New York University; the samples were obtained from 49 asbestos-exposed persons in whom mesothelioma developed and 96 asbestos-exposed, cancer-free controls. Fibulin-3 was measured in the blinded serum, and the results were then unblinded and analyzed by CARET coinvestigators. Princess Margaret Hospital in Toronto contributed deidentified, blinded plasma samples collected from 48 patients with mesothelioma and 96 asbestosexposed, cancer-free persons as part of an approved mesothelioma screening trial. 9 Fibulin measurements in blinded samples were performed at New York University, with subsequent data unblinding and analyses by the Toronto coinvestigators. Patients with Pleural Effusions Not Due to The Detroit cohort included 53 controls with effusions not due to mesothelioma. Of these patients, 1 had an asbestos-related inflammatory effusion, 2 had chronic inflammation, 1 had congestive heart failure, 2 had spontaneous hydropneumothorax, 2 had an effusion after immunotherapy or chemotherapy, 17 had a postoperative benign effusion, 12 had adenocarcinoma of the lung, 4 had squamous carcinoma of the lung, 8 had lung cancer not otherwise specified, 2 had renal-cell cancer, 1 had breast cancer, and 1 had lymphoma. The New York cohort included 4 controls with effusions not due to mesothelioma. Of these patients, 2 had an asbestos-related inflammatory effusion, 4 had chronic inflammation, 1 had congestive heart failure, 7 had a reactive pleural effusion, 7 had adenocarcinoma of the lung, 2 had squamous carcinoma of the lung, 3 had lung cancer not otherwise specified, 3 had gastrointestinal adenocarcinoma, 1 had renal-cell cancer, 1 had sarcoma, 1 had cancer of an unknown primary site, 5 had breast cancer, 2 had small-cell carcinoma, and 1 had lymphoma. Matching plasma samples were available from 3 of the 4 controls in the New York cohort. Immunohistochemical Analysis Immunohistochemical analysis was performed on 4-μm sections of a formalin-fixed, paraffinembedded tissue microarray from a previously constructed 26-patient tissue microarray (with tissue samples obtained from randomly selected patients with mesothelioma for whom 2 to 4 cores of tumor and 2 cores of non-neoplastic pleural tissue, lung tissue, or both were available) with the use of mouse antihuman fibulin-3 antibody, clone mab3-5 (Santa Cruz Biotechnology) (see the Supplementary Appendix). For each core, both nuclear staining and cytoplasmic staining for fibulin-3 were scored (with the scorer unaware of the tissue microarray key) for the proportion of cells stained (on a scale from to 5, with higher scores indicating a greater proportion of stained cells) and intensity of staining (on a scale from to 3, with higher scores indicating a greater intensity of staining). A total score (range, to 15, with higher scores indicating more cells positive for mesothelioma) was given for mesothelioma cells and the non-neoplastic mesothelial and submesothelial pleural tissue. Fibulin-3 Enzyme-Linked Immunosorbent Assay Levels of fibulin-3 in plasma and pleural effusions were measured in duplicate wells and quantified in nanograms per milliliter with the use of the human fibulin-3 enzyme-linked immunosorbent assay (USCN Life Science). Statistical Analysis Kaplan Meier survival plots and log-rank tests were used to assess differences in survival according to the stage of disease in the patients with mesothelioma and according to levels of fibulin-3 in plasma and effusions in all participants. The ability of n engl j med 367;15 nejm.org october 11, Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
6 plasma fibulin-3 levels to distinguish cohorts was evaluated by means of descriptive statistics specifically, the Mann Whitney test for independent samples, without correction for multiple comparisons, and receiver-operating-characteristic (ROC) curves. 1,11 The area under the ROC curve (AUC) was calculated, and 95% confidence intervals were used to test the hypothesis that the AUC is.5. 11,12 We calculated differences between groups by using analysis of variance and multiple regression analysis in a stepwise fashion, entering only variables with a P value of less than.5 in the model. Spearman s rank-correlation coefficients were calculated to assess the correlation between groups. All statistical analyses were performed with the use of MedCalc software. No adjustment of P values for multiple comparisons was planned; when such an adjustment was made, the results were unchanged. R esult s Plasma Fibulin-3 Levels Mean plasma fibulin-3 levels differed significantly between asbestos-exposed, cancer-free persons and patients with mesothelioma (Table 1) in both cohorts, and plasma fibulin-3 levels in patients with mesothelioma in the Detroit cohort were similar to those in patients with mesothelioma in the New York cohort (mean [±SE], 15.±7.1 ng per milliliter and 112.9±7.6 ng per milliliter, respectively; 95% confidence interval [CI] for the difference, 14.8 to 28.6; P =.63). Plasma fibulin-3 levels did not differ significantly between 44 patients with mesothelioma who received preoperative chemotherapy and 48 who did not (117.9±8.1 ng per milliliter and 11.1±6.9 ng per milliliter, respectively; 95% CI for the difference, 37.8 to 4.3; P =.12). No relationship was seen between plasma fibulin-3 levels and duration of asbestos exposure or radiographic score in patients in the New York cohort or those in the Detroit cohort; the mean (±SE) duration of exposure in the two cohorts was 34±1 years and 21±2 years, respectively. Plasma fibulin-3 levels were also not influenced by the patient s age or sex or by the histologic subtype of mesothelioma. Plasma fibulin-3 levels in patients with stage I or II mesothelioma were similar to those in patients with stage III or IV disease (Fig. S2 in the Supplementary Appendix) and did not differ significantly according to overall survival (data not shown). Simultaneously obtained serum and plasma samples from 2 patients had similar fibulin-3 levels, with a correlation coefficient of.94 (95% CI,.84 to.98), although serum values were significantly lower than plasma values ( ng per milliliter vs ng per milliliter, P =.6). ROC Curves In the Detroit cohort, the AUC for asbestosexposed, cancer-free persons as compared with patients with mesothelioma was 1.. A cutoff value of 32.9 ng per milliliter had the highest accuracy (minimal false negative and false positive results) for mesothelioma detection (sensitivity, 1% [95% CI, 9.5 to 1]; specificity, 1% [95% CI, 91.4 to 1]). These data were independently confirmed in the New York cohort, with an AUC of.99 at a cutoff level of 52.8 ng per milliliter for the highest accuracy (sensitivity, 94.6% [95% CI, 84.9 to 98.9]; specificity, 95.7% [95% CI, 89.6 to 98.8]). When the Detroit and New York cohorts were combined, the AUC was.99 at a cutoff level of 52.8 ng per milliliter for the highest accuracy in a comparison of plasma samples from 92 patients with mesothelioma with plasma samples from all 29 controls (Fig. 1A). Plasma fibulin-3 levels differentiated patients with mesothelioma from patients with benign or malignant effusions not due to mesothelioma and also from patients who had other cancers without effusions (Table 2). When the 28 patients with stage I or II mesothelioma were compared with asbestos-exposed controls, the AUC was.99 at a cutoff level of 46. ng per milliliter (sensitivity, 1% [95% CI, 87.7 to 1]; specificity, 94.1% [95% CI, 88.7 to 97.4]) (Fig. 1B). Fibulin-3 levels fell after cytoreductive surgery in 18 of 18 patients with mesothelioma (Fig. 2C), with a trend toward increased levels at the time of confirmed histologic or cytologic progression in 6 patients. Validation Studies The validation study with serum samples obtained from CARET participants failed to discriminate between patients with and those without malignant pleural mesothelioma (AUC,.56 [University of California, Los Angeles] and.52 [New York University]). Serum samples from CARET participants were collected from 1985 through 1996, and we noted that even in fresh 1422 n engl j med 367;15 nejm.org october 11, 212 Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
7 Fibulin-3 as a Marker of Table 2. Area under the ROC Curve (AUC), Sensitivity, and Specificity According to Study Cohort.* Comparison No. of Participants AUC (95% CI) Cutoff Sensitivity at 1% Specificity Specificity at 1% Sensitivity ng/ml percent Patients with mesothelioma vs. all controls 92 vs ( ) Patients with mesothelioma vs. asbestos-exposed 92 vs ( ) persons Asbestos-exposed persons vs. healthy persons without 136 vs ( ) asbestos exposure Patients with mesothelioma vs. patients with benign 92 vs ( ) effusions Patients with mesothelioma vs. patients with malignant 92 vs ( ) effusions not due to mesothelioma Patients with mesothelioma vs. all patients with effusions 92 vs ( ) not due to mesothelioma Patients with mesothelioma vs. controls without effusions 92 vs ( ) * CI denotes confidence interval. specimens collected simultaneously and stored for less than 2 years, the serum levels were significantly lower than the plasma levels. We were concerned that serum fibulin-3 measurements, particularly in old, archived specimens, might not be accurate, especially since analysis of the structure of fibulin-3 revealed at least two thrombin cleavage sites 13 similar to those of fibulin Hence, we performed another blinded validation study using plasma samples collected at Princess Margaret Hospital. Excellent discrimination between the 96 controls and the 48 patients with mesothelioma was found (AUC,.87). At a specificity of 1%, a sensitivity of 33% was achieved (Fig. 2D). Effusion Fibulin-3 Levels There was a surprisingly poor correlation between fibulin-3 levels in matched samples of plasma and pleural effusions from 17 patients with mesothelioma (correlation coefficient,.7; 95% CI,.486 to.475; P =.98) as well as in samples of plasma and pleural effusions from 15 patients with effusions not due to mesothelioma (correlation coefficient,.35; 95% CI,.245 to.77; P =.27). effusions had significantly higher fibulin-3 levels than either benign effusions or malignant effusions not due to mesothelioma (Table 1). The effusion fibulin-3 levels did not differ significantly between 22 patients who received preoperative chemotherapy and 52 who did not (617.4±72.5 ng per milliliter and 73.6±42.6 ng per milliliter, respectively; 95% CI for the difference, 74.7 to 246.9; P =.54). ROC Curves Fibulin-3 levels in effusions discriminated between patients with mesothelioma and participants without the condition in both the Detroit and New York cohorts, with AUCs of.95 and.91, respectively, and the cutoffs for maximum sensitivity and specificity were similar (378 ng per milliliter and 346 ng per milliliter) (Table S1 in the Supplementary Appendix). As shown in Figures 2A, 2B, and 2C, fibulin-3 levels discriminated effusions from patients with mesothelioma from effusions from all other participants (AUC,.93), whether they had benign effusions (AUC,.93) or malignant effusions (AUC,.94). Among 54 patients who underwent cytoreductive surgery and pathological staging, effusion fibulin-3 levels differed significantly between the 21 patients with stage I or II mesothelioma and the 33 patients with stage III or IV disease (576±67 ng per milliliter vs. 765±55 ng per milliliter, P =.4) (Fig. 2D). Moreover, when we used as a cutoff value the median effusion fibulin-3 level (733.4 ng per milliliter) in all 69 patients with malignant pleural mesothelioma who underwent cytoreductive surgery and for whom survival information was available, survival differed significantly according to the effusion fibulin-3 level at the time of surgery (Fig. 2E). A multivariate model revealed that the cutoff effusion fibulin-3 level, stage of dis- n engl j med 367;15 nejm.org october 11, Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
8 A All Effusions Not Due to versus Effusions 1 B Benign Effusions versus Effusions 1 C Malignant Effusions Not Due to versus Effusions Sensitivity, 83.8% Specificity, 92.4% Cutoff, >346.1 ng/ml 95% CI for the AUC, Sensitivity, 83.8% Specificity, 92.4% Cutoff, >346.1 ng/ml Sensitivity, 78.4% Specificity, 94.9% Cutoff, > ng/ml 95% CI for the AUC, Sensitivity, 78.4% Specificity, 94.9% Cutoff, > ng/ml Sensitivity, 83.8% Specificity, 97.6% Cutoff, >346.1 ng/ml 95% CI for the AUC, Minus Percent Specificity Sensitivity, 83.8% Specificity, 97.6% Cutoff, >346.1 ng/ml Effusion Fibulin-3 (ng/ml) Effusion Fibulin-3 (ng/ml) Minus Percent Specificity Effusion Fibulin-3 (ng/ml) Nonmesothelioma Effusions Effusions Minus Percent Specificity Benign Effusions Effusions Nonmesothelioma Malignant Effusions Effusions D Pathological Stage and Effusion Fibulin-3 Level in Patients with Maximal Cytoreduction E Survival According to Effusion Fibulin-3 Level among Patients with Maximal Cytoreduction 16 1 Hazard ratio, 2.7 (95% CI, ) P=.4 P< ng/ml <733.4 ng/ml Effusion Fibulin-3 (ng/ml) Probability of Survival (%) 2 Stage I or II Stage III or IV No. at Risk <733.4 ng/ml ng/ml Months n engl j med 367;15 nejm.org october 11, 212 Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
9 Fibulin-3 as a Marker of Figure 2 (facing page). Effusion Fibulin-3 Levels. Panel A, B, and C show the ROC curves for patients with mesothelioma as compared with all patients with effusions not due to mesothelioma, patients with benign effusions, and patients with malignant effusions not due to mesothelioma, respectively; the diagram at the bottom of each panel shows the cutoff point at highest accuracy. Panel D shows effusion fibulin-3 levels according to pathological stage in patients with mesothelioma who underwent cytoreductive surgery. Unlike plasma fibulin-3 levels, effusion fibulin-3 levels differed significantly between patients with early-stage mesothelioma and those with late-stage mesothelioma. Panel E shows effusion fibulin-3 levels and survival among patients with mesothelioma who underwent cytoreductive surgery. Higher fibulin-3 levels were associated with significantly poorer survival. ease, and histologic subtype were independently predictive of survival (Table S2 in the Supplementary Appendix). Additional prognostic cutoff-point modeling is described in the Supplementary Appendix. Immunohistochemical Studies Nuclear expression of fibulin-3, cytoplasmic expression of fibulin-3, or both were seen in the mesothelioma cells of 26 out of 26 specimens, and the staining-intensity scores were similar when the epithelial histologic subtype (mean score, 7.7±.6) was compared with the mixed epithelial-and-sarcomatoid biphasic histologic subtype (6.9±.8; 95% CI for the difference, 1.2 to 3.; P =.87) or with purely sarcomatoid histologic subtypes (6.6±1.1; 95% CI for the difference, 2.6 to 4.9; P =.62). The total staining score (for both nuclear and cytoplasmic fibulin-3 staining) was consistently higher for the neoplastic mesothelioma components than for the non-neoplastic pleura (7.4±.5 [range, to 15] vs. 2.4±.8 [range, to 12]; 95% CI for the difference, 6.9 to 3.1; P<.1) (Fig. S4 in the Supplementary Appendix). Discussion The results of our study suggest that levels of fibulin-3 in plasma and effusions may aid in determining the diagnosis and prognosis of pleural mesothelioma. The specificity and sensitivity of fibulin-3 in discriminating between asbestosexposed persons, as well as patients with effusions not due to mesothelioma, and patients with mesothelioma are superior to those of other published markers, and fibulin-3 levels are not influenced by the duration of asbestos exposure. In addition, high levels of fibulin-3 in effusions have a high positive predictive value for the presence of mesothelioma and appear to reflect the prognosis. Fibulin-3 is a highly conserved member of the extracellular glycoprotein fibulin family encoded by the gene epidermal growth factor containing fibulin-like extracellular matrix protein 1 (EFEMP1) on chromosome 2p Gene expression is low in normal tissues, with the highest expression in the thyroid. 16 Fibulin-3 is expressed in condensing mesenchyme, giving rise to bony and cartilaginous structures. 17 It mediates cell-to-cell and cell-tomatrix communication, is inversely related to cell growth, and has variable angiogenic effects. 18,19 Inactivation of EFEMP1 due to DNA hypermethylation has been reported in lung, 2,21 prostate, 22 colorectal, 23 breast, 24 nasopharyngeal, 25 and hepatocellular 26 carcinomas. In contrast, fibulin-3 is up-regulated in pancreatic adenocarcinoma metastases, 27 and there are conflicting opinions about whether the elevated expression of fibulin-3 enhances or suppresses invasion of glioblastomas. 28,29 A single study of differences in gene expression between ovarian or primary peritoneal serous carcinomas and diffuse malignant peritoneal mesothelioma showed that EFEMP1 was overexpressed in all the mesotheliomas but in none of the ovarian or serous carcinomas. 3 In hereditary maculopathy, overexpression of fibulin-3 is associated with a mutation in EFEMP1. 31,32 We have not detected any mutations in the EFEMP1-coding exons of 2 pleural mesotheliomas (data not shown). The plasma fibulin-3 level was significantly elevated in patients with mesothelioma in the two separate geographic cohorts (Detroit and New York), and these elevations were confirmed in a blinded validation with the use of specimens from Toronto. The characteristics of the patients with mesothelioma in the Detroit and New York cohorts were similar, including their mean plasma fibulin-3 levels. Plasma fibulin-3 levels discriminated between stage I or II mesothelioma and asbestos exposure without mesothelioma, at a specificity of 94% and a sensitivity of 1%, and the similarity of plasma fibulin-3 levels in earlyand late-stage disease suggests that fibulin-3 may be associated with early events in mesothelial transformation. Surprisingly, effusion fibulin-3 levels did not correlate with plasma levels. Cavitary levels of fibulin-3 may reflect the biology of n engl j med 367;15 nejm.org october 11, Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
10 mesothelioma more accurately than plasma levels, because an advanced stage of disease was associated with higher effusion fibulin-3 levels, and effusion fibulin-3 levels (in contrast to plasma levels) were independently prognostic in patients who underwent complete staging at the time of cytoreductive surgery. Only effusion levels of vascular endothelial growth factor (VEGF) have been associated with prognosis in patients with mesothelioma 33 ; however, VEGF levels cannot discriminate between effusions due to mesothelioma and effusions not due to mesothelioma. 34 The data from this study cannot support a conclusion that fibulin-3 is an early detection marker for mesothelioma, owing to the lack of prospective, plasma-based longitudinal collections. Our CARET data suggest that plasma, not serum, should be used for fibulin measurement, because of the possibility of uncontrolled thrombin cleavage. Further validation studies of plasma fibulin-3, as well as the prognostic implications of an elevated fibulin-3 level, must be performed as part of an international effort to investigate the management of a rising plasma fibulin-3 level and to determine the number of years before clinical onset that plasma fibulin-3 can be used to detect mesothelioma. Moreover, the role of fibulin-3 as a monitoring biomarker after treatment for the disease should be prospectively validated, since we report that plasma fibulin-3 levels fell dramatically after surgical cytoreduction and rose at the time of progression. The precision of the cutoff points defined in this study for maximal sensitivity and specificity in the detection of disease will also need to be examined in further studies. Although the values for plasma fibulin-3 were similar in our cohorts, the cutoffs varied between the two geographic cohorts. This could be due to heterogeneity of the cohorts (specifically, the health of asbestos-exposed persons as compared with that of patients with cancer) or the effects of batching assays. Finally, fibulin-3 levels must be measured in more asbestos-exposed patients with benign effusions, which will require a prospective trial. Future investigations should also explore why fibulin-3 is selectively elevated in mesothelioma as compared with other cancers and should address the question of whether this is an epigeneticbased phenomenon either through methylation or microrna control. These studies could potentially clarify the role of fibulin-3 in mesothelioma growth, invasion, and metastasis formation and determine whether the molecule might be targeted for specific cytotoxic or biologic therapies. Supported by the Princess Margaret Hospital Foundation and the Princess Margaret Hospital Research Program (funded by the Masters Insulators Association of Ontario, International Association of Heat and Frost Insulators and Asbestos Workers, Local 793, and other unions, and the Imperial Oil Charitable Foundation) for plasma banking; by the M. Qasim Choksi Chair in Lung Cancer Translational Research (held by Dr. Tsao), the Alan B. Brown Chair in Molecular Genetics (held by Dr. Liu), and the Ontario Ministry of Health and Long-Term Care; and by donations from Belluck and Fox, the Simmons Foundation, Levi Phillips and Konigsberg, the Stephen E. Banner Fund for Lung Cancer Research, the Rosenwald Family, and the Anderson Family and grants from the Early Detection Research Network, National Institutes of Health, to the New York University Thoracic Oncology Research Laboratories (U1 CA ) and to Beth Israel Deaconess Medical Center (U1 CA ). Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank Joseph Levin, Laura Linker, Ryan Harrington, Jean Reiss, and Stephanie Krauter for technical assistance; Mike Mehan for statistical consultation; and our collaborators who provided control plasma samples for our studies: Dr. David Zagzag, Neuropathology Department, New York University, New York; Dr. Paul Engstrom and JoEllen Weaver, Fox Chase Cancer Center, Philadelphia; Dr. Sylvia Formenti, Dr. Leonard Liebes, and Michelle Malanga, NYU Cancer Institute, New York; and Dr. Martin Sanda and Jonathan Noel, Beth Israel Deaconess Medical Center, Boston. References 1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 23;21: Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 29;21: Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 212;3: Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 25;353: Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 24;1: Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;18: Selikoff IJ, Seidman H. Use of death certificates in epidemiological studies, including occupational hazards: variations in discordance of different asbestos-associated diseases on best evidence ascertainment. Am J Ind Med 1992;22: Barnhart S, Keogh J, Cullen MR, et al. The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts. Am J Ind Med 1997;32: Roberts HC, Patsios DA, Paul NS, et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 29;4: Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8: n engl j med 367;15 nejm.org october 11, 212 Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
11 Fibulin-3 as a Marker of 11. Zweig MH, Campbell G. Receiveroperating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39: [Erratum, Clin Chem 1993;39:1589.] 12. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143: Tran H, Mattei M, Godyna S, Argraves WS. Human fibulin-1d: molecular cloning, expression and similarity with S1-5 protein, a new member of the fibulin gene family. Matrix Biol 1997;15: Sasaki T, Mann K, Murphy G, Chu ML, Timpl R. Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases. Eur J Biochem 1996;24: Zhang Y, Marmorstein LY. Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res 21;9: Kobayashi N, Kostka G, Garbe JH, et al. A comparative analysis of the fibulin protein family: biochemical characterization, binding interactions, and tissue localization. J Biol Chem 27;282: Moore RM, Redline RW, Kumar D, et al. Differential expression of fibulin family proteins in the para-cervical weak zone and other areas of human fetal membranes. Placenta 29;3: Segade F. Molecular evolution of the fibulins: implications on the functionality of the elastic fibulins. Gene 21;464: Albig AR, Neil JR, Schiemann WP. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 26;66: Kim EJ, Lee SY, Woo MK, et al. Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol 212;4: Yue W, Dacic S, Sun Q, et al. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 27;13: Kim YJ, Yoon HY, Kim SK, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 211;17: Tong JD, Jiao NL, Wang YX, Zhang YW, Han F. Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma 211;58: Sadr-Nabavi A, Ramser J, Volkmann J, et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 29;124: Hwang CF, Chien CY, Huang SC, et al. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol 21;222: Nomoto S, Kanda M, Okamura Y, et al. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 21;17: Seeliger H, Camaj P, Ischenko I, et al. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 29;7: Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 29;7: Hu Y, Pioli PD, Siegel E, et al. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer 211; 1: Davidson B, Stavnes HT, Holth A, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med 211;15: Michaelides M, Jenkins SA, Brantley MA Jr, et al. Maculopathy due to the R345W substitution in fibulin-3: distinct clinical features, disease variability, and extent of retinal dysfunction. Invest Ophthalmol Vis Sci 26;47: Roybal CN, Marmorstein LY, Vander Jagt DL, Abcouwer SF. Aberrant accumulation of fibulin-3 in the endoplasmic reticulum leads to activation of the unfolded protein response and VEGF expression. Invest Ophthalmol Vis Sci 25;46: Hirayama N, Tabata C, Tabata R, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med 211;15: Fiorelli A, Vicidomini G, Di DM, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interact Cardiovasc Thorac Surg 211;12:42-4. Copyright 212 Massachusetts Medical Society. icmje seeking two new member journals The International Committee of Medical Journal Editors (ICMJE) is seeking two new member journals to be represented by their editors-in-chief. Information about the ICMJE is available at Candidate journals should meet the following criteria: be a peer-reviewed general medical journal that publishes original research involving humans have a governance structure that ensures editorial independence have an editor with experience in the position who expects to continue in the position for at least another 3 years be financially able to support the editor s participation in ICMJE activities In considering candidates, the ICMJE may seek to improve the balance of geographic areas and publishing models among its membership. To apply, editors-in-chief of interested journals should submit the following materials to the ICMJE (at brief curriculum vitae cover letter describing the journal, including but not necessarily limited to details of the journal s history, sponsor or publisher, governance structure, publishing model (e.g., subscription, author-pays open access), target audience, print circulation and online traffic, number of manuscript submissions per year, processes used to select material for publication, acceptance rate, databases where indexed, website address, and guidelines for authors statement on how the journal might benefit from ICMJE membership and how the ICMJE might benefit from the journal s membership (should not exceed 1 words) The deadline for applications is January 31, 213. n engl j med 367;15 nejm.org october 11, Downloaded from nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on November 1, 212. For personal use only. No other uses without permission. Copyright 212 Massachusetts Medical Society. All rights reserved.
original article Fibulin-3 as a Blood and Effusion Biomarker for Pleural Harvey I. Pass, M.D., Stephen M. Levin, M.D., Michael R. Harbut, M.D., Jonathan Melamed, M.D., Luis Chiriboga, Ph.D., Jessica Donington,
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.4.1403 RESEARCH ARTICLE Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma Halide Kaya 1 *, Melike Demir 1, Mahsuk Taylan 1, Cengizhan
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions Harvey I. Pass, Anil Wali, Naimei Tang, Alla Ivanova, Sergey Ivanov, Michael Harbut, Michele Carbone and Jeffrey
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 email@example.com
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:
For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
The RNA strategy RNA as a tool and target in human disease diagnosis and therapy. The Laboratory of RNA Biology and Biotechnology at the Centre for Integrative Biology (CIBIO) of the University of Trento,
MESOMARK, Brochure Interest in any of the products, request or order them at Bio-Connect Diagnostics. Bio-Connect Diagnostics B.V. T NL +31 () 3 T BE +3 () 5 1 53 Begonialaan 3a F NL +31 () 3 1 F BE +3
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow (firstname.lastname@example.org) Uma R Chandran (email@example.com)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
Mesothelioma Michele Carbone, M.D.,PH.D. Director Cancer Research Center of Hawaii Professor and Chairman, Dept. of Pathology J.A. Burns Medical School University of Hawaii Honolulu, HI 96813 Mesotheliomas
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
Tropical Journal of Pharmaceutical Research December 2010; 9 (6): 605-613 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Review Article
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
DIAPHRAGM DIAgnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma Kevin Blyth Consultant Respiratory Physician, Southern General Hospital NRS Research Fellow & Honorary Clinical
microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS 1st International Congress on Controversies in Personalized Oncology (CONPO) BARCELONA, SPAIN MARCH
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition firstname.lastname@example.org September 23, 2010 Screening: 3 tests for PCa A good screening
PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON* M. L. Newhouse TUC Centenary Institute of Occupational Health London School of Hygiene and Tropical Medicine London WCIE 7HT. England G. Berry
APPENDIX 1 NHS Barking and Dagenham Briefing on disease linked to Asbestos in Barking & Dagenham 1. Background 1.1. Asbestos Asbestos is a general name given to several naturally occurring fibrous minerals
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
Individual patient data meta-analysis of continuous diagnostic markers J.B. Reitsma Julius Center for Health Sciences and Primary Care UMC Utrecht / www.juliuscenter.nl Outline IPD benefits Meta-analytical
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers
Early Detection Research Network: Validation Infrastructure Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention 15 October 2015 Mission The NCI Early Detection Research Network s (EDRN) mission is to implement
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; email@example.com (2) Steven
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
An Update on Lung Cancer Diagnosis Dr Michael Fanning MBBS FRACGP FRACP RESPIRATORY AND SLEEP PHYSICIAN Mater Medical Centre Outline Risk factors for lung cancer Screening for lung cancer Radiologic follow-up
Pleura Visceral pleura covers lungs and extends into fissures Parietal pleura limits mediastinum and covers dome of diaphragm and inner aspect of chest wall. Two layers between them (pleural cavity) contains
Testimony of Dr. James Crapo April 26, 2005 Written Statement of Dr. James D. Crapo, Professor of Medicine, National Jewish Medical and Research Center and University of Colorado Health Sciences Center
Carbohydrate antigen 19 9 (CA 19 9) (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Carbohydrate antigen 19 9 (CA 19 9) 1.2 Alternative names Cancer antigen 19 9, cancer antigen GI
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents
MALIGNANT PLEURAL FLUIDS AID MESOTHELIOMA CELL GROWTH AND PROPAGATION HUI MIN CHEAH PhD Candidate School of Medicine and Pharmacology University of Western Australia Lung Institute of Western Australia
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis . Most are
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate
Personalized Predictive Medicine and Genomic Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov brb.nci.nih.gov Powerpoint presentations
Mesothelioma Research Program Program Update 2012 We are pleased to provide you with an update of progress made over the past year in the Mesothelioma Research Program at The Princess Margaret / University
Biomarkers for early detection of asbestosassociated cancers ( study) G. Johnen, B. Pesch, D. Weber, K. Gawrych, S. Casjens, I. Raiko, O. Bryk, D. Taeger, S. Meier, P. Rozynek, T. Wiethege, G. Aguilar-Madrid,
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
Personalized Treatment for Malignant Mesothelioma RN Taub (Onc) J Chabot (Surg) A Borczuk (Path) J Sonnet (Surg) M Kluger (Surg) R Fawwaz (Nuc. Med) E Hare (Onc) Columbia University Mesothelioma Center
Case based applications part III Los Angeles Society Of Pathologists January 25, 2014 Sanja Dacic, MD, PhD University of Pittsburgh Medical Center 1 CASE 1 A 44-year-old woman with multiple lung nodules.
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
Uses and Abuses of Pathology in Asbestos-exposed Populations Jerrold L. Abraham, MD Department of Pathology State University of New York Upstate Medical University Syracuse, NY, 13210 USA The term: Asbestosis,
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
An Introduction to Cancer and Basic Cancer Vocabulary Marc B. Garnick, MD Beth Israel Deaconess Medical Center Harvard Medical School, Boston Medical Director Cancer Programs Northeast Hospital Corporation,
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
Pathologist s Discussion of Plaintiffs Latest Theories Mary Beth Beasley, MD Mt. Sinai Medical Center Annenberg Building 15th Floor Room 50 1468 Madison Avenue New York, NY 10029 (212) 241-5307 firstname.lastname@example.org
CHEST Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma* Jenette Creaney, PhD; Ivonne van Bruggen, BSc; Michelle Hof, BSc; Amanda Segal, MBBS; Arthur W. Musk, MBBS, MD, FCCP;
CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin 16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
Abnormalities Consistent with Asbestos-Related Disease Among Long-Term Demolition Workers Stephen M. Levin, M.D. Mount Sinai School of Medicine New York, New York November 1994 The Center to Protect Workers
International Journal of Case Reports in Medicine Vol. 2013 (2013), Article ID 409830, 15 minipages. DOI:10.5171/2013.409830 www.ibimapublishing.com Copyright 2013 Andrew Thomas Low, Iain Smith and Simon